TGTX Shares Rise as Early Trial of CAR‑T Therapy Shows Promise for Progressive MS

Investors got a bit of good news on Friday when TG Therapeutics (TGTX) disclosed early results from a Phase 1 trial of its experimental cell therapy for progressive multiple sclerosis. The stock nudged up roughly 4% – a modest bump, but notable because the broader biotech market was actually slipping.

The study focused on patients whose disability was still worsening despite standard treatments. After a 90‑day course of Azer‑cel, 89% of the evaluable participants either maintained or improved their disability scores, and five individuals even showed measurable gains.

Azer‑cel is a CAR‑T cell product that uses genetically edited immune cells harvested from healthy donors. Rather than being a bespoke, patient‑specific therapy, it’s built as an “off‑the‑shelf” solution that targets CD19, a protein on B‑cells that play a role in the disease’s pathology.

Importantly, the trial didn’t flag any severe CAR‑T‑related toxicities or dose‑limiting side effects. Still, the data are preliminary, and TG Therapeutics says it will push ahead with higher‑dose cohorts and longer‑term follow‑up to confirm durability.

Beyond Azer‑cel, TG already has a marketed drug, Briumvi, for relapsing forms of multiple sclerosis, and an injectable version is moving through Phase 3 with read‑outs expected in early 2027. The company is also testing the same platform in Phase 2 trials for myasthenia gravis and treatment‑resistant schizophrenia.

Financially, TG sits on a healthy balance sheet – about $612 million in cash and equivalents as of June 30, 2026, a sharp rise from the $199 million it reported at the end of 2025. That cash cushion gives the firm room to keep expanding its pipeline.

On social‑trading platform Stocktwits, the sentiment around TGTX remained bullish, with users calling the data “fantastic news” and suggesting it could re‑price the stock. So far, TGTX shares have climbed nearly 90% year‑to‑date, outperforming many of its peers.